Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00109161

Recruitment Status : Completed

First Posted : April 25, 2005

Last Update Posted : August 5, 2008

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by:

Facet Biotech

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Primary Completion Date :	No date given
Study Completion Date :	October 2006

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Erratum In: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].

To Top